A Clinical Trial Evaluating TG4050 in Head and Neck Cancer

Summary

This is a multicenter, open-label, two arms, randomized, phase I/II study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with squamous cell carcinoma of the head and neck (SCCHN).

Timeline

Start

2019-12-12

Primary completion

2027-12-30

Completion

2031-12-30

Drugs

Indications